"Interferon-beta" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the type I interferons produced by fibroblasts in response to stimulation by live or inactivated virus or by double-stranded RNA. It is a cytokine with antiviral, antiproliferative, and immunomodulating activity.
| Descriptor ID |
D016899
|
| MeSH Number(s) |
D12.644.276.374.440.890.275 D12.776.467.374.440.890.275 D23.529.374.440.890.275
|
| Concept/Terms |
Interferon-beta- Interferon-beta
- Interferon beta
- Interferon, Fibroblast
- Fibroblast Interferon
- Interferon, beta
- beta Interferon
- beta-Interferon
beta-1 Interferon- beta-1 Interferon
- beta 1 Interferon
- Interferon-beta1
- Interferon beta1
- Interferon, beta-1
- Interferon, beta 1
|
Below are MeSH descriptors whose meaning is more general than "Interferon-beta".
Below are MeSH descriptors whose meaning is more specific than "Interferon-beta".
This graph shows the total number of publications written about "Interferon-beta" by people in this website by year, and whether "Interferon-beta" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 2 | 1 | 3 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 2 | 3 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 2 | 5 | 7 |
| 2017 | 11 | 17 | 28 |
| 2018 | 9 | 13 | 22 |
| 2019 | 4 | 10 | 14 |
| 2020 | 9 | 8 | 17 |
| 2021 | 3 | 8 | 11 |
To return to the timeline, click here.
Below are the most recent publications written about "Interferon-beta" by people in Profiles.
-
Beta interferons as immunotherapy in multiple sclerosis: a new outlook on a classic drug during the COVID-19 pandemic. QJM. 2021 Dec 20; 114(10):691-697.
-
Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial. Trials. 2021 Sep 03; 22(1):584.
-
SARS-CoV-2 suppresses IFNß production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon. PLoS Pathog. 2021 08; 17(8):e1009800.
-
A cluster randomized trial of interferon ß-1a for the reduction of transmission of SARS-Cov-2: protocol for the Containing Coronavirus Disease 19 trial (ConCorD-19). BMC Infect Dis. 2021 Aug 13; 21(1):814.
-
SARS-CoV-2 NSP12 Protein Is Not an Interferon-ß Antagonist. J Virol. 2021 08 10; 95(17):e0074721.
-
IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition in vitro. Nat Commun. 2021 07 28; 12(1):4584.
-
Interferon ß, an enhancer of the innate immune response against SARS-CoV-2 infection. Microb Pathog. 2021 Sep; 158:105105.
-
Epigenetic and transcriptional control of interferon-ß. J Exp Med. 2021 09 06; 218(9).
-
SARS-CoV-2 N Protein Targets TRIM25-Mediated RIG-I Activation to Suppress Innate Immunity. Viruses. 2021 07 23; 13(8).
-
Sex Differences in Lung Imaging and SARS-CoV-2 Antibody Responses in a COVID-19 Golden Syrian Hamster Model. mBio. 2021 08 31; 12(4):e0097421.